

ABSTRACT OF THE DISCLOSURE

The pharmaceutical preparations for treating side effects, such as hot flashes, prostate enlargement and gynecomastia, during and/or after treatment with analogs or antagonists of gonadotropin-releasing hormone (GnRHa therapy) 5 contain an effective amount of a chemically modified derivative of 17 α -estradiol, a chemically modified derivative of 17 β -estradiol and/or a chemical modified derivative of estriol. Pharmaceutical preparations containing estra 1,3,5(10)-triene-3,17 β -diol-17-valerate as the effective ingredient are particularly preferred.